Abstract
Simple SummaryTo better prevent/combat recurrence and identify predictive/targetable markers upon diagnosis, we performed whole-exome sequencing (WES) of primary tumours and relapses of human papillomavirus positive (HPV+) tonsillar and base of tongue cancer (TSCC/BOTSCC) on patients treated with curative intent, with and without relapse. A specific deletion in the CDC27 gene was observed only in the primaries of 5/17 patients that recurred but in none of the 18 patients without recurrence. Furthermore, three specific variants and 26 mutated genes enriched in mucins were identified in at least 30% of all primaries irrespective of recurrence. To conclude, a specific CDC27 deletion could be specific for recurrent HPV+ TSCC/BOTSCC, while BCLAF1, AQP7 and other globally mutated genes could be of significance for further investigation.To identify predictive/targetable markers in human papillomavirus positive (HPV+) tonsillar and base of tongue cancer (TSCC/BOTSCC), whole-exome sequencing (WES) of tumours of patients with/without recurrence was performed. Forty primary tumours and adjacent normal tissue were separated by micro-dissection from formalin-fixed paraffin-embedded tissue from patients treated with curative intent 2000–2014 at Karolinska University Hospital. Successful sequencing was obtained in primary tumours of 18 patients without and primaries of 17 with local or distant recurrence, as well as in 10 corresponding recurrences (i.e., five local relapses and five distant metastases) from these 17 patients. One variant—a high-impact deletion in the CDC27 gene—was observed only in primaries of 5/17 patients that had a recurrence after full treatment but in none of those without recurrence. In addition, 3 variants and 26 mutated genes, including CDC27, BCLAF1 and AQP7, were present in at least 30% of all primary tumours independent of prognosis. To conclude, a CDC27 deletion was specific and found in ~30% of samples from patients with a local relapse/distant metastasis and could, therefore, potentially be a prospective marker to predict prognosis. Commonly mutated genes, such as BCLAF1, should be further studied in the context of targeted therapy.
Highlights
Human papillomavirus positive (HPV+ ) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) patients have a better prognosis compared to those withHPV-negative (HPV− ) TSCC/BOTSCC and other head and neck squamous cell carcinoma (HNSCC), but 15–20% still relapse [1,2,3,4]
Since the incidences of HPV+ TSCC and BOTSCC, the two oropharyngeal squamous cell carcinoma (OPSCC) subsites, where HPV is mainly found, are rising epidemically in many Western countries, improved therapeutic options are crucial for these patients [5,6,7,8,9,10,11,12]
HPV+ TSCC/BOTSCC patients are often offered induction or concomitant chemoradiotherapy, but this has still not improved the survival of those with poor prognosis when compared to the previously given radiotherapy and surgery highlighting the need for new therapeutic options [13,14]
Summary
Human papillomavirus positive (HPV+ ) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) patients have a better prognosis compared to those withHPV-negative (HPV− ) TSCC/BOTSCC and other head and neck squamous cell carcinoma (HNSCC), but 15–20% still relapse [1,2,3,4]. Human papillomavirus positive (HPV+ ) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) patients have a better prognosis compared to those with. Since the incidences of HPV+ TSCC and BOTSCC, the two oropharyngeal squamous cell carcinoma (OPSCC) subsites, where HPV is mainly found, are rising epidemically in many Western countries, improved therapeutic options are crucial for these patients [5,6,7,8,9,10,11,12]. HPV+ TSCC/BOTSCC patients are often offered induction or concomitant chemoradiotherapy, but this has still not improved the survival of those with poor prognosis when compared to the previously given radiotherapy and surgery highlighting the need for new therapeutic options [13,14]. To improve patient stratification and individual tailoring of therapy, efforts have been made to uncover novel prognostic markers in HPV+ TSCC/BOTSCC/OPSCC [14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39].
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have